Clinically, non-selective myostatin inhibitors have led to unwanted side effects, such as gingival bleeding and telangiectasias, as well as alterations in hormone levels, believed to be the result of BMP9 and Activin A inhibition, respectively (54,59). This evidence concerns the gene MSTN and Telangiectasia.